CRCM  Vol.1 No.2 , December 2012
Acute liver failure following levetiracetam therapy for seizure prophylaxis in traumatic brain injury
Abstract: This case report investigates an uncommon occurrence of drug induced acute liver injury directly associated with the administration of levetiracetam in a patient following traumatic brain injury.
Cite this paper: Syed, A. and Adams, C. (2012) Acute liver failure following levetiracetam therapy for seizure prophylaxis in traumatic brain injury. Case Reports in Clinical Medicine, 1, 42-45. doi: 10.4236/crcm.2012.12010.

[1]   Ramael, S., Daoust, A., Otoul, C., et al. (2006) Levetiracetam intravenous infusion: A randomized, placebo- controlled safety and pharmacokinetic study. Epilepsia, 47, 1128-1135. doi:10.1111/j.1528-1167.2006.00586.x

[2]   Lyseng-Williamson, K.A. (2011) Levetiracetam: A review of its use in epilepsy. Drugs, 71, 489-514.

[3]   Walker, M.C. and Patsalos, P.N. (1995) Clinical pharma- cokinetics of new antiepileptic drugs. Pharmacology & Therapeutics, 67, 351-384. doi:10.1016/0163-7258(95)00021-6

[4]   Brockmoller, J., Thomsen, T., Wittstock, M., Coupez, R., Lochs, H. and Roots, I. (2005) Pharmacokinetics of levetiracetam in patients with moderate to severe liver cirrhosis (child-pugh classes A, B, and C): Characterization by dynamic liver function tests. Clinical Pharmacology & Therapeutics, 77, 529-541.

[5]   Droz-Perroteau, C., et al. (2010) Eulev cohort study rates of and factors associated with continuation of levetiracetam after 1 year. Beer Judge Certification Program, 77, 121-127.

[6]   Tan, T.C., de Boer, B.W. and Mitchell, A., et al. (2008) Levetiracetam as a possible cause of fulminant liver fail- ure. Neurology, 71, 685-686. doi:10.1212/01.wnl.0000324604.11657.c6

[7]   Skopp, G., Schmitt, H.P. and Pedal, I. (2006) Fulminant liver failure in a patient on carbamazepine and levetiracetam associated with status epilepticus. Archiv für Kriminologie, 217, 161-175.

[8]   Feeney, D.M. and Walker, A.E. (1979) The prediction of posttraumatic epilepsy. A mathematical approach. Archives of Neurology, 36, 8-12. doi:10.1001/archneur.1979.00500370038005

[9]   Naranjo, C.A., Busto, U., Sellers, E.M., Sandor, P., Ruiz, I., Roberst, E.A., et al. (1981) A method for estimating the probability of adverse drug reactions. Clinical Phar- macology & Therapeutics, 30, 239-245. doi:10.1038/clpt.1981.154

[10]   Hill, A.B. (1965) The environment and disease: Association or causation? Proceedings of the Royal Society of Medicine, 58, 295-300.

[11]   Lee, W.M. (2003) Drug-induced hepatotoxicity. The New England Journal of Medicine, 349, 474-485. doi:10.1056/NEJMra021844

[12]   Navarro, V.J. and Senior, J.R. (2006) Drug-related heaptotoxicity. The New England Journal of Medicine, 354, 731-739. doi:10.1056/NEJMra052270

[13]   Alvestad, S., Lydersen, S. and Brodtkorb, E. (2008) Cross-reactivity pattern of rash from current antiepileptic drugs. Epilepsy Research, 80, 194-200. doi:10.1016/j.eplepsyres.2008.04.003

[14]   Ahmed, S.N. and Siddiqi, Z.A. (2006) Antiepileptic drugs and liver disease. Seizure, 15, 156-164. doi:10.1016/j.seizure.2005.12.009